Research
Hormonal
Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.
Practitioners should adopt a long-term management strategy for obesity treatment.
StrongSupportsmedium confidence
Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.
Why this rating
The claim is based on expert opinion derived from the review.
Source
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Alvin Mondoh et al. · Expert Opinion on Pharmacotherapy · 2025
DOI 10.1080/14656566.2025.2601060
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →